Sigyn Therapeutics, Inc. (SIGY) — 10-Q Filings

10-Q Filings (6)

• Sigyn Pivots to CardioDialysis Amidst Deep Losses, Going Concern Doubts — Nov 14, 2025 Risk: high
  Sigyn Therapeutics, Inc. (SIGY) reported no revenue for the nine months ended September 30, 2025, consistent with the prior year. The company's net loss decreas
• Sigyn Therapeutics' Net Loss Widens Amid Zero Revenue, Cash Dwindles — Sep 5, 2025 Risk: high
  Sigyn Therapeutics, Inc. (SIGY) reported a net loss of $2,119,751 for the six months ended June 30, 2025, a significant increase from the $1,620,471 net loss fo
• Sigyn Therapeutics Files 10-Q for Q1 2025 — May 20, 2025 Risk: low
  Sigyn Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Reign Resources Corp and Reign Sapphire Corp, is inco
• Sigyn Therapeutics Files 10-Q for Q3 2024 — Nov 19, 2024 Risk: low
  Sigyn Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Reign Resources Corp and Reign Sapphire Corp, is
• Sigyn Therapeutics Files Q2 2024 10-Q — Aug 19, 2024 Risk: medium
  Sigyn Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the company, w
• Sigyn Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  Sigyn Therapeutics, Inc. (SIGY) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Sigyn Therapeutics, Inc. filed a 10-Q report for the quarterly per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX